Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2010

01-12-2010 | Short communication

Designing adjuvant treatment based on biological measurements in the neoadjuvant setting

Authors: Ian E Smith, Aekaterini Kotsori

Published in: Breast Cancer Research | Special Issue 4/2010

Login to get access

Excerpt

For many years, one of the main aims of neoadjuvant therapy has been to identify short term endpoints that will predict for long-term outcome in adjuvant treatment. The advantages are obvious: in contrast to adjuvant trials, neoadjuvant trials require hundreds rather than thousands of patients, are very much less expensive to run and produce outcome data many years earlier. …
Literature
1.
Alba E, Calvo L, Albanell J, De la Haba J, Chacon J, Arcusa Lanza A, Sanchez Roviraet P: Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: a multicenter, randomized phase II study (GEICAM/2006-03) [abstract]. J Clin Oncol. 2010, 28: 15s-
2.
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001, 30: 96-102.CrossRef
3.
Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerman DL, Wolmark : National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003, 21: 4165-4174. 10.1200/JCO.2003.12.005.CrossRefPubMed
4.
Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006, 24: 2019-2027. 10.1200/JCO.2005.04.1665.CrossRefPubMed
5.
Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005, 23: 5108-5116. 10.1200/JCO.2005.04.005.CrossRefPubMed
6.
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008, 26: 1059-1065. 10.1200/JCO.2007.12.9437.CrossRefPubMed
7.
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, IMPACT Trialists: Short-term changes in Ki67 during neo adjuvant treatment of primary breast cancer with anastrazole or tamoxifen alone or combined correlate with recurrence free survival. Clin Cancer Res. 2005, 11: 951s-968s.PubMed
8.
Jones RL, Smith IE: Neoadjuvant treatment for early-stage breast cancer:opportunities to assess tumour response. Lancet Oncology. 2006, 7: 869-874. 10.1016/S1470-2045(06)70906-8.CrossRefPubMed
9.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahon AA, Ewer MS, Buchholz RA, Berry D, Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. JCO. 2005, 23: 3676-3685. 10.1200/JCO.2005.07.032.CrossRef
10.
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010, 375: 377-384. 10.1016/S0140-6736(09)61964-4.CrossRefPubMed
11.
Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Pritchard K, Laing K, Provencher L, Charbonneau LF: Adjuvant targeted therapy in early breast cancer. Cancer. 2009, 115: 1154-1168. 10.1002/cncr.24114.CrossRefPubMed
12.
Slamon D, Eiermann W, Robert N: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study [abstract]. Cancer Res. 2009, 69: 500s-
13.
Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004, 91: 2012-2017. 10.1038/sj.bjc.6602235.CrossRefPubMedPubMedCentral
14.
Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M: The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009, 116: 53-68. 10.1007/s10549-008-0081-7.CrossRefPubMed
15.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010, 11: 174-183. 10.1016/S1470-2045(09)70262-1.CrossRefPubMed
Metadata
Title
Designing adjuvant treatment based on biological measurements in the neoadjuvant setting
Authors
Ian E Smith
Aekaterini Kotsori
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 4/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2745

Other articles of this Special Issue 4/2010

Breast Cancer Research 4/2010 Go to the issue

Introduction

Controversies in Breast Cancer 2010

Short communication

Contribution of biomarkers to personalized medicine

Short communication

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics

Short communication

Are current development programs realising the full potential of new agents?

Short communication

Classical peer review: an empty gun

Short communication

Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits